EAGAN, Minn.--(BUSINESS WIRE)--Imprime PGG®, the phase 3 cancer immunotherapy drug from Biothera, utilizes distinct receptors and signaling pathways in monocytes to induce cytotoxic function. The research was published in the latest issue of Glycobiology.